Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
For many people, the autumn/winter zone between Thanksgiving and Christmas can be one of the bleakest slogs of the year. Can you think of a better way to kick that off than the most doom-laden concert ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Are you mentally prepared for some heavy-ass shit? You better be mentally prepared for some heavy-ass shit if you're going to hit play on this one. The Denver noise-metal power trio Primitive Man will ...
Virginia Beach-based Born Primitive is bringing its patriot-inspired workout apparel to the Hilltop shopping district. The e-commerce clothing brand, co-founded in a garage in 2014 by former Navy SEAL ...
During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results